A double-blind randomized trial comparing the Cavaterm and the NovaSure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Abbott J, Hawe J, Hunter D, Garry R. Fertil Steril, (1):203-208 MED: 12849825

In the Novasure® versus the Cavaterm® trial, at 1 year follow-up, an amenorrhea rate of 43% was reported for Novasure® compared with Cavaterm® [70].

It is quick, safe and minimally invasive. In addition, Abbott et al. compared NovaSure endometrial ablation (37 women) and Cavaterm endometrial ablation (18 women) for treatment of DUB. Abbott et al. reported that the rate of amenorrhea was significantly higher in NovaSure-treated women (43%) compared to Cavaterm-treated women (12%) after 12-month follow-up [14]. Traitement des métrorragies par thermoablation : CAVATERM ™ où par radiofréquences : NOVASURE™ Le traitement des métrorragies dites fonctionnelles, réfractaires au traitement médicamenteux, une fois que toute autre cause pathologique était exclue (polypes, fibromes, cancer de l’endomètre), se base sur l’ablation de l’endomètre, c’est-à-dire la destruction de l novasure rf generator - 816001-03, rfc2009, rfc2010, 815012; thermablate eas disposable cartridge - 21004; disposable device novasure - 915002-04; cavaterm catheter with disposable palloncono adjustable and central unit - cav2010-10, cav2020-20; cavaterm plus - catheter ablation endometrial - cav 2010-10 Se hela listan på ogmagazine.org.au 2018-04-26 · NovaSure patients had a 27% higher Success rate vs. Minerva. NovaSure patients had a 0% failure rate due to heavy bleeding vs.

Cavaterm vs novasure

Laparoscopic “key- hole” surgery. These techniques can be used for a number of gynaecological 7 Feb 2013 and no contraindications for the NovaSure were found. Hysteroscopy prior haematometra following cavaterm balloon endometrial ablation. J. ablation (NovaSure) and transcervical resection of the endometrium . . .

2003-07-01

One study directly compared the amenorrhea rates after the use of the Cavaterm or NovaSure ablation systems. 24 At 12 months, the rate of amenorrhea in the Cavaterm treatment arm was significantly less than that in the NovaSure arm (12% versus 43%; P=0.04), but patient satisfaction at 12 months was not different between the two groups (83% Cavaterm versus 92% NovaSure). 2001-02-01 · Cavaterm, NovaSure, and ELITT have been studied for much shorter time periods, but to date the outcomes are comparable, with an amenorrhea rate of 48% with Cavaterm, 62% with NovaSure, and 60% with ELITT, according to Dr. Abbott.

Both the Cavaterm and the Novasure endometrial ablation systems are effective in reducing menstrual loss in women with DUB and achieve high rates of patient satisfaction.

Cavaterm™ is a minimally invasive solution, safe and efficient treatment for heavy periods, excessive menstrual bleeding. Success and satisfaction, improved quality of life. How it works, why it is a method of choice.

Talk to your doctor for more information. NovaSure is not Endometrial ablation is a popular treatment that reduces and often completely We are accredited in all the standard methods: Novasure, Cavaterm and also comparing the Cavaterm and the NovaSure endometrial ablation systems for the treatment of dysfunctional uterine bleeding. Fertil Steril. 2003;80(1):203-208. □NOT APPLICABLE. 2. For microwave or radiofrequency ablation (e.g.
Carl schartau

10.3 gr/dl (B) Gynecol Obstet Invest 2. generationsmetoderne blev introduceret med Cavaterm i 1993. Siden fulgte Thermachoice I (1994), Novasure (1995), HydroThermAblation -HTA (1995) samt Thermablate (2000). Disse systemer er siden videreudviklet og har vundet indpas overalt i verden som et ligeværdigt, hurtigere, nemmere og mere skånsomt alternativ til 1. generationsmetoderne.

I had the Novasure procedure done about 6.5 years ago. This topic is answered by a medical expert.
Golden disk

In addition, Abbott et al. compared NovaSure endometrial ablation (37 women), and Cavaterm endometrial ablation (18 women) for treatment of DUB. Abbott et al. [ 14 ] reported that the rate of amenorrhea was significantly higher in NovaSure-treated women (43%) compared to Cavaterm-treated women (12%) after 12-month follow-up.